Anti-inflammatory actions of intravenous immunoglobulin.
暂无分享,去创建一个
[1] Amos Etzioni,et al. Intravenous immunoglobulin in immunodeficiency states , 2005, Clinical reviews in allergy & immunology.
[2] R. Kimberly,et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. , 1991, Blood.
[3] R. Ober,et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.
[4] Dennis R. Burton,et al. Human antibody–Fc receptor interactions illuminated by crystal structures , 2004, Nature Reviews Immunology.
[5] V. Wahn,et al. Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success , 2005, International Archives of Allergy and Immunology.
[6] R. Geha,et al. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. , 2003, The Journal of allergy and clinical immunology.
[7] J. Ravetch,et al. Divergent roles for Fc receptors and complement in vivo. , 1998, Annual review of immunology.
[8] B. Neel,et al. FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin , 2007 .
[9] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[10] R. Hansen,et al. Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor , 2002, Thrombosis and Haemostasis.
[11] C. Prins,et al. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. , 2007, Acta dermato-venereologica.
[12] S. Akilesh,et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. , 2004, The Journal of clinical investigation.
[13] Lars E French,et al. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. , 2006, Allergology international : official journal of the Japanese Society of Allergology.
[14] T. Lebien,et al. Fates of human B-cell precursors. , 2000, Blood.
[15] J. Marchalonis,et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Tschopp,et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.
[17] S. Kaveri,et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. , 1998, Journal of immunology.
[18] C. Hack,et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. , 2001, Blood.
[19] M. Hulett,et al. Molecular basis of Fc receptor function. , 1994, Advances in immunology.
[20] K. Siminovitch,et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. , 2003, Blood.
[21] J. Ravetch,et al. FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.
[22] K. Sullivan,et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. , 1990, The New England journal of medicine.
[23] R. Dwek,et al. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. , 2006, Immunology letters.
[24] K. Titani,et al. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. , 1990, Journal of immunology.
[25] T. Yamazaki,et al. Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. , 1998, The Journal of clinical investigation.
[26] T. Waldmann,et al. Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia , 2004, Cancer Research.
[27] A. Buchacher,et al. Purification of intravenous immunoglobulin G from human plasma – aspects of yield and virus safety , 2006, Biotechnology journal.
[28] J. Ravetch,et al. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity , 2007, Proceedings of the National Academy of Sciences.
[29] M. Witmer,et al. Blockade of clearance of immune complexes by an anti-F(cγ) receptor monoclonal antibody , 1986, The Journal of experimental medicine.
[30] J. Fehr,et al. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. , 1982, The New England journal of medicine.
[31] S. Molica,et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. , 1996, Haematologica.
[32] R. Dwek,et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. , 1997, Biochemistry.
[33] M. Dalakas,et al. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. , 1994, The Journal of clinical investigation.
[34] R. Steinman,et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[35] A. Cooke,et al. Glycosylation of IgG, immune complexes and IgG subclasses in the MRL‐lpr/lpr mouse model of rheumatoid arthritis , 1990, European journal of immunology.
[36] M. Ono,et al. Augmented humoral and anaphylactic responses in FcγRII-deficient mice , 1996, Nature.
[37] R. Dwek,et al. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Freedman,et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. , 2007, Transfusion medicine reviews.
[39] P. Ricciardi-Castagnoli,et al. Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.
[40] M. Frank,et al. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes , 1991 .
[41] J. Pollard,et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. , 2003, Immunity.
[42] M. Daëron,et al. Fc receptor biology. , 2003, Annual review of immunology.
[43] P. Masson,et al. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. , 1993, Journal of autoimmunity.
[44] R. Dwek,et al. Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.
[45] E. Gelfand. Differences between IGIV products: impact on clinical outcome. , 2006, International immunopharmacology.
[46] M. Frank,et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance , 1989 .
[47] Ralph Weissleder,et al. Arthritis critically dependent on innate immune system players. , 2002, Immunity.
[48] J. Ravetch,et al. The antiinflammatory activity of IgG: the intravenous IgG paradox , 2007, The Journal of experimental medicine.
[49] P. Bruhns,et al. FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .
[50] J. Ravetch,et al. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.
[51] M. Madaio,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[52] Leonard G. Presta,et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.
[53] T. Tedder,et al. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy , 2006, The Journal of experimental medicine.
[54] J. Freedman,et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. , 2003, Blood.
[55] Eric M. Billings,et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins , 2003, Nature Medicine.
[56] J. Freedman,et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? , 2005, The Journal of clinical investigation.
[57] J. Ravetch,et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.
[58] J. Orange,et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.
[59] A. Lazarus,et al. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia , 2006, Pediatric blood & cancer.
[60] D. Hamrock,et al. Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.
[61] R. Dwek,et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. , 1991, Journal of autoimmunity.
[62] S. Miescher,et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. , 2006, Blood.
[63] M. Ono,et al. Modulation of Immune Complex–induced Inflammation In Vivo by the Coordinate Expression of Activation and Inhibitory Fc Receptors , 1999, The Journal of experimental medicine.
[64] B. Scallon,et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. , 2007, Molecular immunology.
[65] M. Kazatchkine,et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) , 1993, Clinical and experimental immunology.
[66] T. Honjo,et al. Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III , 2000, The Journal of experimental medicine.
[67] B. Heyman,et al. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. , 1999, Journal of immunology.
[68] É. Oksenhendler,et al. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti‐D , 1996, Transfusion.
[69] R. Ghirlando,et al. The molecular specificity of IgG-Fc interactions with Fc gamma receptors. , 2001, Advances in experimental medicine and biology.
[70] W. Fridman,et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura , 1993, The Lancet.
[71] S. Kaveri,et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). , 1999, Blood.
[72] J. Ravetch,et al. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. , 1994, Science.
[73] M. Gershwin,et al. Common variable immune deficiency and autoimmunity. , 2006, Autoimmunity reviews.
[74] S. Kaveri,et al. Common variable immunodeficiency: the immune system in chaos. , 2005, Trends in molecular medicine.
[75] H. Simon,et al. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. , 2003, The Journal of allergy and clinical immunology.
[76] M. Ono,et al. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. , 2000, The Journal of experimental medicine.
[77] R. Jefferis,et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. , 1990, The Biochemical journal.
[78] J. Ravetch,et al. Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells , 2002, The Journal of experimental medicine.
[79] J. Ravetch,et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. , 2005, The Journal of clinical investigation.
[80] T. Yoshino,et al. Deletion of Fcγ Receptor IIB Renders H-2b Mice Susceptible to Collagen-induced Arthritis , 1999, The Journal of experimental medicine.
[81] J. Ravetch,et al. Cytotoxic antibodies trigger inflammation through Fc receptors. , 1995, Immunity.
[82] A. Salama,et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)) , 1984, Blut.
[83] J. Ravetch,et al. Fcgamma receptors: old friends and new family members. , 2006, Immunity.
[84] J. Ravetch,et al. Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.
[85] S. Kaveri,et al. Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action , 2007, Journal of Clinical Immunology.
[86] E. Ward,et al. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.
[87] R. Dwek,et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. , 2003, Glycobiology.
[88] M. Carroll,et al. The complement system in regulation of adaptive immunity , 2004, Nature Immunology.
[89] D. Roopenian,et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.
[90] R. Kimberly,et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody , 1986 .
[91] J. Balthasar,et al. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. , 2005, Journal of pharmaceutical sciences.
[92] Pauline M Rudd,et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.
[93] A. Matsumoto,et al. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. , 2000, Journal of biochemistry.
[94] F. Pixley,et al. Biology and action of colony‐stimulating factor‐1 , 1997, Molecular reproduction and development.
[95] Bin Zhou,et al. Multi-dysfunctional pathophysiology in ITP. , 2005, Critical reviews in oncology/hematology.
[96] A. Bitonti,et al. Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade , 2007, The Journal of Immunology.
[97] M. Fanger,et al. Monoclonal antibody 197 (anti‐FcγRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down‐modulation of FcγRI on circulating monocytes , 1996 .
[98] J. Freedman,et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells , 2006, Nature Medicine.
[99] A. Salama,et al. EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA Competitive Inhibition of Reticuloendothelial System Function by Sequestration of Autologous Red Blood Cells? , 1983, The Lancet.
[100] J. Freedman,et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? , 2007, Blood.
[101] A. Hirt,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.
[102] Klaus Rajewsky,et al. The half‐lives of serum immunoglobulins in adult mice , 1988, European journal of immunology.
[103] M. Kazatchkine,et al. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. , 1989, Journal of immunology.